More News! Big Money for a Danish CRO, a Bad Opinion for a Swiss Pharma

Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.
  • Boehringer Ingelheim committed €250M to Danish CRO Gubra in a diabetes deal

  • Sanofi got a slight nod from the FDA for its a biosimilar of Humalog, Eli Lilly’s best-selling insulin
  • Anergis scored a marginal win — 7% improvement — in a Phase IIb designed to test the efficacy of its allergy immunotherapy
  • Santhera’s repurposed Duchenne muscular dystrophy drug, Raxone, got hit with a negative CHMP opinion questioning its efficacy
  • AB Science also suffered a slap from CHMP: the French biotech had requested the reassessment of masitinib in indolent systemic mastocytosis, but the committee was not convinced of a favorable risk-benefit ratio
  • Moderna and its partner, AstraZeneca, have let more light in to show off a newly reorganized R&D structure
  • There’s a new biotech on the Leiden block: TM3 has debuted with a Nature publication as a biotech developing metabolite replacement therapies
  • Finland-based BC Platforms joined forces with Microsoft Genomics to launch a platform to integrate genomic and clinical data
  • Inotrem has a new lead compound in septic shock that just turned up positive preclinical results

Images via nattanan726, kunanon, hkhtt hj, Seregraff /



Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.